<DOC>
	<DOCNO>NCT03015532</DOCNO>
	<brief_summary>This Phase 2b , randomize , double-blind , saline placebo- active-controlled , multicenter study subject undergoing primary unilateral total knee arthroplasty ( TKA ) evaluate analgesic efficacy , safety , pharmacokinetics ( PK ) HTX-011 administer via infiltration surgical site .</brief_summary>
	<brief_title>Total Knee Arthroplasty Infiltration Study Postoperative Analgesia</brief_title>
	<detailed_description />
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Is able provide write informed consent , adhere study visit schedule , complete study assessment . 2 . Is male female , ≥18 year age screening . 3 . Is schedule undergo primary unilateral TKA general spinal anesthesia . 4 . Has American Society Anesthesiologists Physical Status I , II , III . 5 . Is able demonstrate motor function perform time 20meter walk unassisted , optional use 4legged walker balance . 6 . Female subject eligible follow apply : 1 . Not pregnant ( female subject childbearing potential must negative urine pregnancy test screen Day 0 surgery ) . 2 . Not lactate . 3 . Not plan become pregnant study . 4 . Surgically sterile ; least 2 year postmenopausal ; monogamous partner surgically sterile ; practice doublebarrier contraception ; practice abstinence ( must agree use doublebarrier contraception event sexual activity ) ; use insertable , injectable , transdermal , combination oral contraceptive approve US Food Drug Administration ( FDA ) great 2 month prior screen commits use acceptable form birth control duration study 30 day study drug administration . Male subject must sterile ( biologically surgically ) commit use reliable method birth control duration study . A subject follow criterion exclude study : 1 . Has plan concurrent surgical procedure ( eg , bilateral TKA ) . 2 . Has preexist concurrent acute chronic painful/restrictive physical condition may require analgesic treatment postoperative period pain strictly relate knee surgery may confound postoperative assessment . 3 . Has contraindication know suspected history hypersensitivity idiosyncratic reaction bupivacaine ( local anesthetic ) , meloxicam ( NSAIDs ) , oxycodone , morphine , fentanyl , hydromorphone . 4 . Has know suspect daily use opioids 7 consecutive day within previous 6 month . 5 . Has take longacting opioids within 3 day prior surgery , take opioids within 24 hour prior schedule surgery . 6 . Has administer bupivacaine local anesthetic within 72 hour prior schedule surgery , pretreatment prior needle placement . 7 . Initiated treatment follow medication within 1 month prior surgery take medication control pain : selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , gabapentin , pregabalin , duloxetine , COX2 inhibitor . ( Note : If subject take one medication reason pain control , ( ) must stable dose least 1 month prior surgery . ) Anxiolytics prior surgery permit , necessary . 8 . Has medical condition , opinion Investigator , participate study would pose health risk subject . Conditions may include follow : 1 . History clinically significant cardiac abnormality New York Heart Association class III IV , myocardial infarction , result significant clinical abnormality electrocardiogram ( ECG ) function . 2 . History impaired kidney liver function , define aspartate aminotransferase alanine aminotransferase &gt; 3 × upper limit normal ( ULN ) and/or creatinine &gt; 2 × ULN . 3 . History know suspect coagulopathy uncontrolled anticoagulation . 4 . Loss sensation extremity significant peripheral neuropathy . 9 . Has uncontrolled anxiety , psychiatric , neurological disorder might interfere study assessment . 10 . Has chronic neuromuscular deficit either femoral nerve function thigh musculature . 11 . Has chronic condition disease would compromise neurological vascular assessment . 12 . Had malignancy last year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . 13 . Has know suspected history drug abuse positive drug screen , recent history alcohol abuse . 14 . Previously participate HTX011 clinical study receive investigational product clinical trial within 30 day within 5 elimination halflives ( whichever longer ) prior surgery , plan take part another clinical trial participate study . 15 . Has body mass index ( BMI ) &gt; 38 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>